Peer-reviewed veterinary case report
How immune cells in lymph nodes affect chemo-immunotherapy in dogs
By Martini, Valeria et al.·Published in Research in veterinary science·2019·Department of Veterinary Medicine, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy.
- Species:
- dog
Plain-English summary
A group of 59 dogs diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) received a combination of chemotherapy and immunotherapy to treat their cancer. The study found that dogs with a higher percentage of certain immune cells in their lymph nodes had a better response to treatment and a lower chance of the cancer worsening. Specifically, dogs with more small non-cancerous lymphocytes and certain types of immune cells showed improved outcomes. This suggests that the immune system plays an important role in how well dogs respond to treatment for this type of lymphoma.
People also search for: dog lymphoma treatment · DLBCL in dogs · immunotherapy for dog cancer · dog cancer prognosis · lymph node cancer in dogs
Abstract
Dogs with Diffuse Large B-Cell Lymphoma (DLBCL) benefit from the addition of active immunotherapy to traditional chemotherapy. We hypothesized that immune cells within neoplastic lymph nodes (LNs) may play a role in the tumor pathobiology and treatment response. The present study describes the composition and prognostic role of non-neoplastic lymphocytes in LNs of 59 dogs with treatment-naive DLBCL receiving chemo-immunotherapy. The percentage of small non-neoplastic cells and of CD5+, CD21+, CD4+ and CD8+ small cells was recorded via flow cytometry. CD4+/CD8+ and CD5+/large CD21+ cell ratios were calculated. The likelihood of progression significantly diminished with increasing percentage of small cells, CD5+ and CD8+ small cells, and CD5+/large CD21+ cell ratio, with decreasing CD4+/CD8+ ratio and in non-anemic dogs. Active immunotherapy is more effective in dogs with higher percentage of non-neoplastic lymphocytes at diagnosis. We lay the ground for future studies assessing the role of the immune system in the pathobiology of canine DLBCL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31212200/